Řecko - řečtina - Εθνικός Οργανισμός Φαρμάκων

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - levodopa; carbidopa monohydrate; entacapone - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (50+12.5+200)mg/tab - levodopa 50mg; carbidopa monohydrate 13,5mg; entacapone 200mg - levodopa, decarboxylase inhibitor and comt inhibitor

Řecko - řečtina - Εθνικός Οργανισμός Φαρμάκων

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - levodopa; carbidopa monohydrate; entacapone - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (75+18.75+200)mg/tab - levodopa 75mg; carbidopa monohydrate 20,24mg; entacapone 200mg - levodopa, decarboxylase inhibitor and comt inhibitor

Řecko - řečtina - Εθνικός Οργανισμός Φαρμάκων

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - levodopa; carbidopa monohydrate; entacapone - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (150+37,5+200)mg/tab - levodopa 150mg; carbidopa monohydrate 40,48mg; entacapone 200mg - levodopa, decarboxylase inhibitor and comt inhibitor

Řecko - řečtina - Εθνικός Οργανισμός Φαρμάκων

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - levodopa; carbidopa monohydrate; entacapone - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (200+50+200)mg/tab - levodopa 200mg; carbidopa monohydrate 54mg; entacapone 200mg - levodopa, decarboxylase inhibitor and comt inhibitor

Řecko - řečtina - Εθνικός Οργανισμός Φαρμάκων

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - levodopa; carbidopa; entacapone - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (125+31,25+200)mg/tab - levodopa 125mg; carbidopa 31,25mg; entacapone 200mg - levodopa, decarboxylase inhibitor and comt inhibitor

Řecko - řečtina - Εθνικός Οργανισμός Φαρμάκων

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - levodopa; carbidopa monohydrate; entacapone - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (100+25+200)mg/tab - levodopa 100mg; carbidopa monohydrate 27mg; entacapone 200mg - levodopa, decarboxylase inhibitor and comt inhibitor

Evropská unie - španělština - EMA (European Medicines Agency)

mylan ireland limited - lenalidomida - mieloma múltiple - inmunosupresores - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Evropská unie - dánština - EMA (European Medicines Agency)

mylan ireland limited - lenalidomid - multipelt myelom - immunosuppressiva - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Evropská unie - estonština - EMA (European Medicines Agency)

mylan pharmaceuticals limited - olansapiin - schizophrenia; bipolar disorder - psühhoeptikumid - adultsolanzapine on näidustatud skisofreenia ravi. olansapiin on efektiivne, säilitades kliinilist paranemist ajal jätkamine ravi patsientidel, kes on näidanud, esialgne ravi vastuseks. olansapiin on näidustatud ravi mõõduka kuni raske maniakaalse episoodi. patsientidel, kelle maniakaalne episood on vastanud, et olansapiin-ravi, olansapiin on näidustatud kordumise ennetamiseks patsientidel, kellel on bipolaarne häire.

Evropská unie - slovenština - EMA (European Medicines Agency)

mylan pharmaceuticals limited - olanzapín - schizophrenia; bipolar disorder - psycholeptika - adultsolanzapine je indikovaný na liečbu schizofrénie. olanzapínu je účinný pri udržiavaní klinické zlepšenie počas pokračovanie liečby u pacientov, ktorí ukázali, počiatočné reakcie na liečbu. olanzapínu je indikovaný na liečbu stredne silnej až silnej manická epizóda. u pacientov, ktorých manické epizódy reagovala na olanzapínu liečby, olanzapínu je indikovaný na prevenciu recidívy v prípade pacientov s bipolárnou poruchou.